1 | 0.9% w/v isotonic sodium chloride solution | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 50 50 |
2 | 10% nifedipine cream | 1件: Nifedipine Nifedipine | 1件: D00437
D00437
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 50 50 |
3 | 3 MPDN pulse + PDN | - | - | - | - | 1件: 50 50 |
4 | 3 MPDN pulse + PDN + CSA | - | - | - | - | 1件: 50 50 |
5 | 3 MPDN pulse + PDN + MTX | - | - | - | - | 1件: 50 50 |
6 | 35mg | - | - | - | - | 2件: 50 50, 107 |
7 | 44/154/85-C | - | - | - | - | 1件: 50 50 |
8 | 44/196/81-C | - | - | - | - | 1件: 50 50 |
9 | 5% sildenafil cream | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 50 50 |
10 | 56/104/75-C | - | - | - | - | 1件: 50 50 |
11 | 5mg | - | - | - | - | 2件: 50 50, 107 |
12 | Abatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 26件: 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
13 | Abatacept Active Treatment | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 |
14 | Abatacept Delayed-Onset Treatment | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 |
15 | Acthar | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 9件: 2 2, 13, 14, 46, 49, 50, 66, 84, 222 |
16 | Acthar Gel | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 6件: 13 13, 46, 49, 50, 84, 222 |
17 | Ad26.COV2.S | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
18 | Adrenocorticotropic Hormone | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 3件: 13 13, 50, 84 |
19 | Adrenocorticotropic Hormone Gel | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 50 50 |
20 | Ajulemic acid | 1件: Ajulemic acid Ajulemic acid | 1件: D11312
D11312
| 1件: CNR2 CNR2 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 50 50, 51, 299 |
21 | Alendronate | 1件: Alendronic acid Alendronic acid | 1件: D07119
D07119
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 7件: 19 19, 41, 46, 50, 271, 274, 299 |
22 | Alendronate versus alfacalcidol (1-alpha OH vitamin D) | 3件: Alendronic acid Alendronic acid, Alfacalcidol, Vitamin D | 2件: D01518
D01518
,
D07119
| 2件: FDPS FDPS, VDR 💬 | 9件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Terpenoid backbone biosynthesis, Tuberculosis 💬 | 3件: 41 41, 46, 50 |
23 | Alfacalcidol | 1件: Alfacalcidol Alfacalcidol | 1件: D01518
D01518
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 8件: 41 41, 46, 49, 50, 96, 107, 235, 238 |
24 | Alfacalcidol 2 micrograms/ml | 1件: Alfacalcidol Alfacalcidol | 1件: D01518
D01518
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 50 50, 107 |
25 | ALXN1210 | - | - | - | - | 7件: 2 2, 11, 13, 50, 62, 66, 109 |
26 | Anakinra | 1件: Anakinra Anakinra | 1件: D02934
D02934
| 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 16件: 2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299 |
27 | Anti-Beta Interferon (PF-06823859) | - | - | - | - | 1件: 50 50 |
28 | Anti-pandemic H1N1 influenza vaccine | - | - | - | - | 6件: 46 46, 49, 50, 51, 53, 107 |
29 | Apremilast | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 7件: 46 46, 50, 56, 97, 107, 162, 271 |
30 | Apremilast 30mg | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 50 50 |
31 | BAF312 | - | - | - | - | 2件: 13 13, 50 |
32 | BAF312 0,5 mg tablet | - | - | - | - | 1件: 50 50 |
33 | BAF312 0.25 mg | - | - | - | - | 1件: 50 50 |
34 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 |
35 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 |
36 | BAF312 0.5 mg | - | - | - | - | 1件: 50 50 |
37 | BAF312 0.50 mg | - | - | - | - | 1件: 50 50 |
38 | BAF312 1 mg | - | - | - | - | 1件: 50 50 |
39 | BAF312 1 mg tablet | - | - | - | - | 2件: 13 13, 50 |
40 | BAF312 1mg | - | - | - | - | 1件: 50 50 |
41 | BAF312 1mg tablet | - | - | - | - | 1件: 50 50 |
42 | BAF312 2 mg | - | - | - | - | 1件: 50 50 |
43 | BAF312 2 mg tablet | - | - | - | - | 1件: 50 50 |
44 | BAF312 2mg | - | - | - | - | 1件: 50 50 |
45 | BAF312 4mg tablet | - | - | - | - | 1件: 50 50 |
46 | BAF312 5 mg tablet | - | - | - | - | 1件: 50 50 |
47 | BAF312 hemifumarate | - | - | - | - | 2件: 13 13, 50 |
48 | BAF312X | - | - | - | - | 1件: 50 50 |
49 | Baricitinib | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 13件: 2 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325 |
50 | Basiliximab | 1件: Basiliximab Basiliximab | 1件: D03058
D03058
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 5件: 2 2, 50, 97, 222, 228 |
51 | Begelomab | 1件: Begelomab Begelomab | - | - | - | 1件: 50 50 |
52 | BNT162b2 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
53 | BNT162b2, Bivalent | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
54 | Brepocitinib | - | - | - | - | 2件: 49 49, 50 |
55 | Calcineurin Inhibitors | - | - | - | - | 1件: 50 50 |
56 | CD7 CAR T-cells | - | - | - | - | 3件: 50 50, 96, 97 |
57 | Cervarix | 1件: Human papillomavirus type 16 L1 capsid protein antigen Human papillomavirus type 16 L1 capsid protein antigen | - | - | - | 3件: 49 49, 50, 107 |
58 | Cervarix suspensie voor injectie | 1件: Human papillomavirus type 16 L1 capsid protein antigen Human papillomavirus type 16 L1 capsid protein antigen | - | - | - | 3件: 49 49, 50, 107 |
59 | Chloride | 1件: Chloride ion Chloride ion | - | - | - | 28件: 6 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 288, 296, 297, 299, 338 |
60 | Ciclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 13件: 26 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 |
61 | Continue IS (B cell depletion therapy) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
62 | Continue IS (MMF or MPA) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
63 | Continue IS (MTX) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
64 | Creapure | - | - | - | - | 1件: 50 50 |
65 | Creatine | 1件: Creatine Creatine | - | - | - | 11件: 1 1, 2, 5, 6, 8, 46, 49, 50, 113, 156, 201 |
66 | CsA | - | - | - | - | 8件: 19 19, 49, 50, 53, 60, 63, 222, 228 |
67 | CyA | - | - | - | - | 2件: 50 50, 222 |
68 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 44件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 |
69 | Cyclophosphamide Injection 1g | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 3件: 50 50, 51, 52 |
70 | Cyclosporin | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 17件: 38 38, 46, 49, 50, 53, 56, 60, 62, 63, 93, 95, 97, 113, 164, 222, 274, 326 |
71 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
72 | Cyclosporine A | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 11件: 19 19, 20, 36, 49, 50, 53, 58, 60, 107, 234, 283 |
73 | Daxdilimab | 1件: Daxdilimab Daxdilimab | 1件: D11778
D11778
| 1件: LILRA4 LILRA4 💬 | 2件: B cell receptor signaling pathway B cell receptor signaling pathway, Osteoclast differentiation 💬 | 2件: 49 49, 50 |
74 | Denosumab | 1件: Denosumab Denosumab | 1件: D03684
D03684
| 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 8件: 46 46, 50, 70, 93, 95, 96, 274, 299 |
75 | Dosage of cytokines | - | - | - | - | 1件: 50 50 |
76 | Drops | - | - | - | - | 2件: 50 50, 107 |
77 | Dual-therapy | - | - | - | - | 1件: 50 50 |
78 | EMEA/H/C/000701 | - | - | - | - | 1件: 50 50 |
79 | Etanercept | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 15件: 15 15, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 |
80 | Gamma Globulin | - | - | - | - | 2件: 15 15, 50 |
81 | GB-0998 | - | - | - | - | 1件: 50 50 |
82 | Gevokizumab | 1件: Gevokizumab Gevokizumab | 1件: D09911
D09911
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 4件: 41 41, 50, 56, 269 |
83 | GLPG3667 | - | - | - | - | 1件: 50 50 |
84 | Glucose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 12件: 2 2, 6, 13, 49, 50, 66, 86, 88, 96, 97, 257, 299 |
85 | Glucose Tablet | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 50 50 |
86 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 63, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 167, 171, 193, 218, 222, 224, 226, 227, 230, 271, 291, 296, 298, 310, 318 |
87 | Grapefruit | 1件: Grapefruit Grapefruit | - | - | - | 5件: 6 6, 46, 50, 83, 97 |
88 | H.P. Acthar Gel | 1件: Corticotropin Corticotropin | 1件: D00146
D00146
| 1件: MC2R MC2R 💬 | 5件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 5件: 46 46, 49, 50, 84, 222 |
89 | H5G1.1-mAb | - | - | - | - | 3件: 13 13, 50, 62 |
90 | HBVAXPRO | - | - | - | - | 2件: 46 46, 50 |
91 | Hizentra | - | - | - | - | 4件: 14 14, 50, 51, 65 |
92 | HUMAN IMMUNOGLOBULIN G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 14 14, 50, 63, 65 |
93 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 |
94 | Human normal immunoglobulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 50, 65 |
95 | Human normal immunoglogulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 50 50 |
96 | Humanised IgG1K monoclonal antibody against interferon beta | 1件: Human interferon beta Human interferon beta | - | - | - | 1件: 50 50 |
97 | IFN-K | - | - | - | - | 2件: 49 49, 50 |
98 | IFN-Kinoid | - | - | - | - | 2件: 49 49, 50 |
99 | IFN-Kinoid Drug Substance | - | - | - | - | 2件: 49 49, 50 |
100 | IFNa-Kinoid | - | - | - | - | 2件: 49 49, 50 |
101 | Ig VENA | - | - | - | - | 2件: 50 50, 63 |
102 | Ig VENA (10g/200mL) | - | - | - | - | 1件: 50 50 |
103 | IgPro20 | - | - | - | - | 4件: 14 14, 50, 51, 65 |
104 | IGVENA*FL 200ML 10G+SET | - | - | - | - | 2件: 14 14, 50 |
105 | Immunoglobulin (Hizentra) | - | - | - | - | 1件: 50 50 |
106 | IMMUNOGLOBULIN G | - | - | - | - | 8件: 2 2, 11, 13, 14, 49, 50, 63, 65 |
107 | IMMUNOSUPPRESSIVE AGENTS | - | - | - | - | 2件: 13 13, 50 |
108 | IMO-8400 | - | - | - | - | 1件: 50 50 |
109 | IMO-8400 Dose Group 1 | - | - | - | - | 1件: 50 50 |
110 | IMO-8400 Dose Group 2 | - | - | - | - | 1件: 50 50 |
111 | Impact | - | - | - | - | 5件: 46 46, 50, 53, 85, 299 |
112 | Infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 26件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
113 | Influvac | 1件: Haemagglutinin-strain B Haemagglutinin-strain B | - | - | - | 3件: 46 46, 49, 50 |
114 | Interferon Beta | 1件: Human interferon beta Human interferon beta | - | - | - | 6件: 13 13, 20, 26, 50, 96, 97 |
115 | INTERLEUKIN-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 10件: 2 2, 35, 49, 50, 53, 55, 65, 96, 97, 162 |
116 | Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung | - | - | - | - | 1件: 50 50 |
117 | IVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 7件: 11 11, 13, 14, 17, 50, 51, 65 |
118 | JAK inhibitor | - | - | - | - | 2件: 46 46, 50 |
119 | JBT-101 | - | - | - | - | 4件: 49 49, 50, 51, 299 |
120 | KZR-616 | 1件: KZR-616 KZR-616 | - | - | - | 3件: 49 49, 50, 61 |
121 | KZR-616 maleate | 1件: KZR-616 KZR-616 | - | - | - | 1件: 50 50 |
122 | L0133 | - | - | - | - | 1件: 50 50 |
123 | Lenabasum | - | - | - | - | 3件: 50 50, 51, 299 |
124 | Lipid-lowering agents (Artovastatin) | - | - | - | - | 1件: 50 50 |
125 | LY3009104 | - | - | - | - | 6件: 46 46, 49, 50, 93, 107, 325 |
126 | M5049 high dose | - | - | - | - | 2件: 49 49, 50 |
127 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
128 | MEDI-545 | - | - | - | - | 2件: 49 49, 50 |
129 | MEDI7734 | - | - | - | - | 1件: 50 50 |
130 | Methimazole | 1件: Methimazole Methimazole | 1件: D00401
D00401
| 1件: TPO TPO 💬 | 4件: Autoimmune thyroid disease Autoimmune thyroid disease, Metabolic pathways, Thyroid hormone synthesis, Tyrosine metabolism 💬 | 1件: 50 50 |
131 | Methotrexat | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 4件: 13 13, 46, 50, 96 |
132 | Methotrexat Lachema 2,5mg | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
133 | Methotrexat Lachema 2,5mg tbl. | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
134 | Methotrexat Lachema 5 inj. sol | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
135 | Methotrexate | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
136 | Methotrexate Lachema 5inj. sol | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
137 | Methotrexate Wyeth 2,5mg | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
138 | Methotrexate Wyeth 2,5mg tbl. | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
139 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 46件: 2 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 |
140 | METHYLPREDNISOLONE SODIUM SUCCINATE | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 6件: 13 13, 46, 49, 50, 51, 211 |
141 | Methylprednisoloni natrii succinas | - | - | - | - | 1件: 50 50 |
142 | Metoject 10 mg/ml | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 50 50 |
143 | Metotrexat | - | - | - | - | 2件: 50 50, 96 |
144 | Metotrexate | - | - | - | - | 1件: 50 50 |
145 | MMF | - | - | - | - | 16件: 13 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 107, 162, 222, 224, 226, 299 |
146 | Moderna mRNA-1273 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
147 | Moderna mRNA-1273, Bivalent | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
148 | Monovalent [B.1.351] CoV2 preS dTM-AS03 | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
149 | MPA | - | - | - | - | 8件: 13 13, 35, 46, 49, 50, 51, 60, 107 |
150 | MTX | - | - | - | - | 14件: 13 13, 35, 40, 46, 49, 50, 51, 60, 84, 96, 97, 107, 162, 271 |
151 | NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 |
152 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 50 50 |
153 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 |
154 | Nifedipine | 1件: Nifedipine Nifedipine | 1件: D00437
D00437
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 50 50, 81 |
155 | Nimenrix | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 50 50, 61 |
156 | Nivolumab | 1件: Nivolumab Nivolumab | 1件: D10316
D10316
| 1件: PDCD1 PDCD1 💬 | 3件: Cell adhesion molecules Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬 | 12件: 13 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159 |
157 | Octagam 10% | - | - | - | - | 3件: 50 50, 63, 65 |
158 | Octanorm | - | - | - | - | 2件: 50 50, 65 |
159 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 |
160 | One Alpha | - | - | - | - | 2件: 50 50, 107 |
161 | One Alpha Drops | - | - | - | - | 2件: 50 50, 107 |
162 | One-alpha | 1件: Alfacalcidol Alfacalcidol | 1件: D01518
D01518
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 50 50, 107 |
163 | One-Alpha drops | 1件: Alfacalcidol Alfacalcidol | 1件: D01518
D01518
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 50 50, 107 |
164 | ORENCIA | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 14件: 44 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 160, 222, 271 |
165 | Orencia (trade name) | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 |
166 | PF-06823859 | - | - | - | - | 1件: 50 50 |
167 | PF-06823859 high | - | - | - | - | 1件: 50 50 |
168 | PF-06823859 low | - | - | - | - | 1件: 50 50 |
169 | Pharmacokinetics study | - | - | - | - | 1件: 50 50 |
170 | Pirfenidone | 1件: Pirfenidone Pirfenidone | 1件: D01583
D01583
| 6件: CCL2 CCL2, IL10, IL1A, IL1B, IL6, TNF 💬 | 84件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Chemokine signaling pathway, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Staphylococcus aureus infection, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
171 | Placebo | - | - | - | - | 28件: 3 3, 5, 6, 11, 13, 14, 37, 40, 46, 49, 50, 51, 53, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 |
172 | Placebo IV | - | - | - | - | 1件: 50 50 |
173 | Placebo SC | - | - | - | - | 1件: 50 50 |
174 | PN-101 | - | - | - | - | 1件: 50 50 |
175 | Pneumovax 23 | 1件: Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 1 capsular polysaccharide antigen | - | - | - | 2件: 46 46, 50 |
176 | Prednisolon | - | - | - | - | 7件: 46 46, 50, 51, 66, 95, 96, 97 |
177 | Prednisolon Pfizer | - | - | - | - | 2件: 46 46, 50 |
178 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 42件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
179 | PREDNISON 5, 20 Léciva por. tablet nob | - | - | - | - | 1件: 50 50 |
180 | Prednison 5, 20 Léciva por. tablet nob. | - | - | - | - | 1件: 50 50 |
181 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 45件: 2 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 |
182 | RAVULIZUMAB | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 7件: 2 2, 11, 13, 50, 62, 66, 109 |
183 | Resunab, ajulemic acid, anabasum | 1件: Ajulemic acid Ajulemic acid | 1件: D11312
D11312
| 1件: CNR2 CNR2 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 50 50, 51, 299 |
184 | Risedronate | 1件: Risedronic acid Risedronic acid | 1件: D08484
D08484
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 7件: 46 46, 50, 66, 96, 107, 113, 274 |
185 | RISEDRONATE SODIUM | 1件: Risedronic acid Risedronic acid | 1件: D08484
D08484
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 4件: 50 50, 107, 113, 274 |
186 | RITUXIMAB | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 48件: 11 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
187 | RoActemra | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 11件: 40 40, 41, 44, 46, 50, 51, 86, 107, 266, 271, 331 |
188 | RoActemra 162 mg soluzione iniettabile in siringa preriempita | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 50 50 |
189 | S78989 | - | - | - | - | 3件: 41 41, 50, 56 |
190 | Sildenafil | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 17件: 6 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 |
191 | Siponimid | - | - | - | - | 1件: 50 50 |
192 | SIPONIMOD | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
193 | Siponimod 0.25 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
194 | Siponimod 0.5 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
195 | Siponimod 1 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
196 | Siponimod 2 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
197 | Sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 20件: 6 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 168, 193, 227, 228, 288, 299 |
198 | Sodium Thiosulfate | - | - | - | - | 2件: 50 50, 51 |
199 | Sodium Thiosulfate 10% | - | - | - | - | 2件: 50 50, 51 |
200 | SODIUM THIOSULFATE PENTAHYDRATE | - | - | - | - | 2件: 50 50, 51 |
201 | Solu-Medrol | 1件: Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate | 1件: D05000
D05000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 7件: 13 13, 49, 50, 51, 53, 97, 211 |
202 | Solu-medrol inj. PSO LQF 40mg | 1件: Methylprednisolone hemisuccinate Methylprednisolone hemisuccinate | 1件: D05000
D05000
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 50 50 |
203 | Steroids | - | - | - | - | 7件: 46 46, 50, 51, 63, 66, 96, 97 |
204 | STS | - | - | - | - | 2件: 50 50, 51 |
205 | Tacrolimus | 1件: Tacrolimus Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
206 | TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 2件: 50 50, 171 |
207 | Tetanus protein | - | - | - | - | 1件: 50 50 |
208 | Tetanus toxoid | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 4件: 13 13, 14, 46, 50 |
209 | Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 |
210 | Tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 |
211 | Tofacitinib 5 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 50 |
212 | Transcriptomic analysis | - | - | - | - | 1件: 50 50 |
213 | Treatment defined only by active substance | - | - | - | - | 1件: 50 50 |
214 | Triple therapy | - | - | - | - | 2件: 50 50, 63 |
215 | Ultomiris | 1件: Ravulizumab Ravulizumab | 1件: D11054
D11054
| 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 6件: 2 2, 11, 13, 50, 62, 66 |
216 | Umbilical Cord Lining Stem Cells | - | - | - | - | 1件: 50 50 |
217 | Ustekinumab | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 16件: 37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
218 | VIB7734 | - | - | - | - | 4件: 49 49, 50, 51, 53 |
219 | Vitamin D | 1件: Vitamin D Vitamin D | - | - | - | 20件: 13 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 179, 222, 228, 235, 274, 298, 299 |
220 | Withhold IS (B cell depletion therapy) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
221 | Withhold IS (MMF or MPA) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
222 | Withhold IS (MTX) | - | - | - | - | 7件: 13 13, 35, 46, 49, 50, 51, 107 |
223 | XOMA 052 | - | - | - | - | 5件: 41 41, 46, 50, 56, 106 |
224 | Yellow fever vaccine | 1件: Yellow fever vaccine Yellow fever vaccine | 1件: D06347
D06347
| - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 |
225 | Yellow Fever vaccine (17D) | 1件: Yellow fever vaccine Yellow fever vaccine | 1件: D06347
D06347
| - | - | 8件: 40 40, 44, 46, 50, 51, 52, 53, 107 |